Harnessing α-Emitting Radionuclides for Therapy: Radiolabeling Method Review

Area of Science:

• Nuclear medicine
• Radiopharmaceutical chemistry
• Oncology

Background:

• Targeted alpha-therapy (TAT) is a promising cancer treatment for advanced stages.
• TAT utilizes targeted radiopharmaceuticals for precise delivery of alpha-emitters.
• Current chelators like DOTA and DTPA have limitations for certain alpha-emitting isotopes.

Purpose of the Study:

• To review methods for incorporating key alpha-emitters into radiopharmaceuticals.
• To focus on new discoveries and remaining challenges in chelator development for TAT.
• To assess the suitability of chelators for isotopes including 225Ac, 212Bi, and others.

Main Methods:

• Literature review of reported methods for radiopharmaceutical development.
• Analysis of chelator chemistry for specific alpha-emitting isotopes (e.g., 149Tb, 211At, 212/213Bi, 212Pb, 223Ra, 225Ac, 226/227Th, 230U).
• Focus on in vivo studies and the identification of ideal chelator-isotope pairings.

Main Results:

• Suitable chelators exist for isotopes like 149Tb, 212/213Bi, 212Pb, 225Ac, and 226/227Th, though further in vivo validation is needed.
• Ideal chelator chemistry remains elusive for isotopes such as 223Ra, 230U, and 211At.
• Significant progress has been made in developing stable chelators for alpha-emitters.

Conclusions:

• The development of effective chelators is crucial for advancing targeted alpha-therapy.
• Continued research is necessary to overcome challenges in chelator design for specific isotopes.
• Optimizing chelator-isotope combinations will enhance the efficacy and safety of TAT for cancer treatment.